https://bioinformatics.umg.eu/onkopus/drugon#antineoplasticagentsimmunological
Properties
- label
- [] antineoplastic agents, immunological
Parents
Children
Relations
- is_mesh
- bemarituzumab
- is_mesh
- tislelizumab
- is_mesh
- alemtuzumab
- is_mesh
- epratuzumab
- is_mesh
- panitumumab
- is_mesh
- abagovomab
- is_mesh
- obinutuzumab
- is_mesh
- glembatumumabvedotin
- is_mesh
- trastuzumab
- is_mesh
- avelumab
- is_mesh
- bevacizumab
- is_mesh
- oregovomab
- is_mesh
- idecabtagenevicleucel
- is_mesh
- necitumumab
- is_mesh
- ipilimumab
- is_mesh
- belatacept
- is_mesh
- dacetuzumab
- is_mesh
- bavituximab
- is_mesh
- amivantamab
- is_mesh
- pembrolizumab
- is_mesh
- rituximab
- is_mesh
- brexucabtageneautoleucel
- is_mesh
- ecromeximab
- is_mesh
- cemiplimab
- is_mesh
- rindopepimut
- is_mesh
- talimogenelaherparepvec
- is_mesh
- adagrasib
- is_mesh
- lintuzumab
- is_mesh
- trastuzumabemtansine
- is_mesh
- rilotumumab
- is_mesh
- nimotuzumab
- is_mesh
- gemtuzumabozogamicin
- is_mesh
- tisagenlecleucel
- is_mesh
- conatumumab
- is_mesh
- inotuzumabozogamicin
- is_mesh
- zalutumumab
- is_mesh
- loncastuximabtesirine
- is_mesh
- pidilizumab
- is_mesh
- zanolimumab
- is_mesh
- lorvotuzumabmertansine
- is_mesh
- abatacept
- is_mesh
- brentuximabvedotin
- is_mesh
- tisotumabvedotin
- is_mesh
- spartalizumab
- is_mesh
- cantuzumabmertansine
- is_mesh
- magrolimab
- is_mesh
- intetumumab
- is_mesh
- durvalumab
- is_mesh
- pertuzumab
- is_mesh
- cetuximab
- is_mesh
- bi836826
- is_mesh
- axicabtageneciloleucel
- is_mesh
- labetuzumab
- is_mesh
- ct011
- is_mesh
- sotorasib
- is_mesh
- nivolumab